MedTrace Logo

Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

NCT05970627 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-08-01

No results posted yet for this study

Summary

This study is a prospective, single arm, multi-center phase II clinical trial designed to evaluate the efficacy and safety of perioperative SOX combined with toripalimab in participants with Epstein-Barr Virus-associated locally advanced gastric or esophagogastric junction adenocarcinoma.

Conditions

  • Adenocarcinoma of the Stomach
  • Adenocarcinoma of Esophagogastric Junction
  • Epstein-Barr Virus-Associated Gastric Carcinoma

Interventions

DRUG

Toripalimab

Perioperative Toripalimab, 240 mg IV infusion

DRUG

Oxaliplatin

Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy

DRUG

S1

S-1 orally intake as perioperative chemotherapy

Sponsors & Collaborators

  • Yu jiren

    lead OTHER

Principal Investigators

  • Jiren Yu · First Affiliated Hospital of Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-28
Primary Completion
2026-07-28
Completion
2029-07-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05970627 on ClinicalTrials.gov